Morning Call, May 23
Health Care: Drugs
Gilead Sciences Inc (GILD: NASDAQ)
$54.70 -1.23 | -2.20%
05/23/13 - 09:50 AM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | 31.30 | 124.60 | 17.70 |
| P/E High - Last 5 Yrs | 27.40 | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | 9.60 | n.a. | 12.50 |
| Beta | 0.51 | 0.63 | 0.98 |
| Price to Sales (TTM) | 8.57 | 6.98 | 1.42 |
| Price to Book (MRQ) | 8.40 | 6.44 | 2.41 |
| Price to Tangible Book (MRQ) | 10.36 | 14.21 | 5.08 |
| Price to Cash Flow (TTM) | 23.80 | 41.40 | 9.80 |
| Price to Free Cash Flow (TTM) | 30.20 | 138.60 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.40 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.30 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 5.57 | 2.80 |
| Payout Ratio (TTM) | 0.00 | 34.00 | 37.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 10.90 | 25.00 | 0.30 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 15.70 | 35.70 | 2.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 15.49 | 11.34 | 3.62 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 17.70 | 99.90 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 17.70 | 99.90 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | 8.12 |
| Capital Spending - 5 Yr Growth Rate (%) | 106.71 | 14.10 | 3.83 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 0.90 | 2.60 | 1.10 |
| Current Ratio (MRQ) | 1.60 | 3.40 | 1.60 |
| LT Debt to Equity (MRQ) | 0.72 | 0.64 | 0.73 |
| Total Debt to Equity (MRQ) | 0.81 | 0.69 | 0.86 |
| Interest Coverage (TTM) | 13.50 | 4.60 | 6.70 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 77.50 | 80.70 | 47.80 |
| Gross Margin - 5 Yr Avg | 79.10 | 82.90 | 47.00 |
| EBITD Margin (TTM) | 45.40 | 22.00 | 19.50 |
| EBITD - 5 Yr Avg | 50.27 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | 39.00 | 11.60 | 11.70 |
| Pre-Tax Margin - 5 Yr Avg | 45.30 | 13.40 | 10.20 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 33.10 | 0.08 | 0.09 |
| Net Profit Margin - 5 Yr Avg | 18.80 | 7.40 | 6.30 |
| Return on Assets (TTM) | 14.80 | 4.20 | 3.20 |
| Return on Assets - 5 Yr Avg | 10.80 | 3.10 | 2.30 |
| Return on Investment (TTM) | 18.90 | 5.40 | 8.50 |
| Return on Investment - 5 Yr Avg | 13.70 | 4.10 | 5.90 |
| Efficiency | |||
| Revenue/Employee (TTM) | 1,990,341.00 | n.a. | n.a. |
| Net Income/Employee (TTM) | 658,262.00 | n.a. | n.a. |
| Receivable Turnover (TTM) | 4.80 | 6.00 | 7.90 |
| Inventory Turnover (TTM) | 1.40 | 1.80 | 7.70 |
| Asset Turnover (TTM) | 0.50 | 0.50 | 0.40 |
Portfolios with GILD
- Portfolio NameUser Type
- ContributorMost-Active Stocks for the ...
- UserDC
- ProHighbridge Capital Management
- ProSteven Cohen - SAC Capital
- ProJohn Griffin - Blue Ridge C...
- UserMike Fatah's Mega Stock Por...
- UserRenzo's portfolio
- ContributorDrugs Facing FDA Approval i...
- UserGFNN Stockdiagnostics 23
- UserBender
Latest GILD Headlines from TheStreet
- Gilead Stock Hits New 52-Week High (GILD) 05.22.13 | 10:05 am
- Gilead Sciences Inc (GILD): Today's Featured Drugs Winner 05.21.13 | 05:05 pm
- Cramer's Top Stock Picks: SAVE GILD BMY HTA TSLA 05.21.13 | 06:05 am
- 5 Stocks Underperforming Today In The Drugs Industry 05.20.13 | 01:05 pm
- Quick Take: The Next Big Thing in Biotech 05.17.13 | 10:05 am
- 'Mad Money' Lightning Round: Magnum Hunter Blew It 05.17.13 | 06:05 am
- Biotech's Next Big Thing ASCO II
05.16.13 | 02:05 pm - ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up 05.15.13 | 06:05 pm
- ASCO '13 Preview: Gilead's Big Cancer Debut 05.15.13 | 06:05 pm
- 5 Stocks Boosting The Drugs Industry Higher 05.15.13 | 01:05 pm
Press Releases for GILD
- Gilead Announces Update On Phase 3 Study Of Oral Fixed-Dose Combination Of Sofosbuvir And Ledipasvir For Genotype 1 Hepatitis C Patients - Business Wire 03.26.13 | 08:03 am
- European CHMP Adopts Positive Opinion For Stribild®, A Once-Daily, Integrase Inhibitor-Based, Single Tablet Regimen For The Treatment Of HIV-1 Infection - Business Wire 03.22.13 | 08:03 am
- Gilead’s Ranexa® Reduces Angina Frequency In Study Of Chronic Angina Patients With Type 2 Diabetes - Business Wire 03.10.13 | 02:03 pm
- Gilead Announces Full 24-Week Phase 2 Results For Once-Daily Single Tablet HIV Regimen Containing Novel Prodrug Tenofovir Alafenamide (TAF) - Business Wire 03.05.13 | 12:03 pm
- Gilead Sciences To Present At The Cowen & Company 33rd Annual Health Care Conference On Monday, March 4 - Business Wire 03.01.13 | 04:03 pm
- Gilead Sciences To Present At Two Upcoming Investor Conferences - Business Wire 02.25.13 | 04:02 pm
- Gilead And Teva Reach Settlement Agreement In Viread® Patent Litigation - Business Wire 02.19.13 | 11:02 pm
- Gilead’s Sofosbuvir For Hepatitis C Meets Primary Endpoint In Fourth Pivotal Phase 3 Study - Business Wire 02.19.13 | 08:02 am
- Gilead Issues A Voluntary Recall Of One Lot Of Vistide® (Cidofovir Injection) Due To Presence Of Particulate Matter - Business Wire 02.15.13 | 06:02 pm
- Gilead Sciences To Present At Two Upcoming Investor Conferences - Business Wire 02.11.13 | 04:02 pm
Partner Headlines for GILD
- Pre-Market Most Active for May 22, 2013 : NTAP, PFE, NMR, RDS/A, RDS/B, NOK, SNE, PGTI, IRWD, GILD, VOD, ZNGA - NASDAQ 05.22.13 | 12:05 pm
- Will Influenza A H7N9 Generate Opportunities For Pharma? - Seeking Alpha 05.21.13 | 09:05 am
- Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 14, 2013 - NASDAQ 05.13.13 | 11:05 am
- Short Interest in Vertex Rises, in Celgene Falls - Benzinga 05.11.13 | 10:05 am
- Techne Corporation (TECH) Ex-Dividend Date Scheduled for May 08, 2013 - NASDAQ 05.07.13 | 01:05 pm
- Leading Biotechs Act Well But Be Careful Not To Chase - Investor's Business Daily 05.06.13 | 06:05 pm
- Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13) - Seeking Alpha 05.05.13 | 06:05 am
- Market Wrap for Friday, May 3: Stocks Jump on Strong Jobs Data - Benzinga 05.03.13 | 04:05 pm
- Inside Wall Street: closer to a cystic fibrosis cure - MSN Money 05.03.13 | 01:05 pm
- Stocks Maintain Early Momentum; Gilead Sciences, Neustar Surge - Investor's Business Daily 05.03.13 | 12:05 pm
